Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $17.1900 (2.32%) ($16.5600 - $17.5700) on Sun. Jun. 14, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.94% (three month average) | RSI | 22 | Latest Price | $17.1900(2.32%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.2% a day on average for past five trading days. | Weekly Trend | TGTX declines -6.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting TGTX price | TGTX will decline at least -3.97% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.97% (StdDev 7.94%) | Hourly BBV | 0 () | Intraday Trend | -0.2% | | | |
|
1 - 5 Day Possible Target | $4.26(-75.22%) | Resistance Level | $18.92 | 5 Day Moving Average | $17.57(-2.16%) | 10 Day Moving Average | $17.84(-3.64%) | 20 Day Moving Average | $18.92(-9.14%) | To recent high | -21.3% | To recent low | 140.8% | Market Cap | $N/A | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |